Q32 Bio Inc. reported in an 8-K filed March 27, 2024 that Shelia Violette was appointed Chief Scientific Officer and President of Research, effective March 25, 2024. The proxy statement of Q32 Bio Inc. reports total compensation of $774,446 for Shelia Violette in fiscal 2025, including a base salary of $455,000. Shelia Violette has spoken on 1 earnings call and 1 other investor event across 1 company, most recently for Q32 Bio Inc. on September 8, 2026. Q32 Bio Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Q32 Bio Inc. includes Albert Seymour, Ph.D. (CEO and Board Member), Jodie Morrison (CEO and Board Member), Paul G. Alloway, Ph.D. (CEO and COO) and 7 others.
“On March 25, 2024, the Board appointed Jodie Morrison as our Chief Executive Officer and principal executive officer, Lee Kalowski as our Chief Financial Officer and President and principal financial officer and principal accounting officer, Jason Campagna as our Chief Medical Officer, and Shelia Violette as our Chief Scientific Officer and President of Research.”
Q32 Bio Inc. Form 8-K, filed March 27, 2024
· Read the filing
Shelia Violette on recent calls
“So a big year for us, obviously, with the readout from the Part B of our Signal program. So an exciting turn for us, I think, as that data matured and we were able to really show that we're in the jack class, sort of as far as the efficacy goes.”
“On slide five, I'll summarize Benpikabart's mechanism of action and impressive biomarker results from our phase two trials. To begin, Benpikabart is a fully human antibody that binds to the IL-7 receptor alpha subunit at a region that is shared for binding by two very important cytokines.”
